Clinical Trials

Phase NA Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07466901 2026-03-12

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

30 enrolled

Uterine Cervical Neoplasms

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3 Recruiting

593 enrolled

Nasopharyngeal Carcinoma

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 3 Not yet recruiting

210 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

246 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

30 enrolled

Advanced Biliary Tract Carcinoma

NCT07400094 2026-02-10

NeoCamre-HN

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2/3 Active not recruiting

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

580 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Phase 3 Active not recruiting

214 enrolled

Carcinoma, Hepatocellular

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3 Recruiting

550 enrolled

Stomach Neoplasms

NCT07314372 2026-01-20

FAD-HCC-001

86 enrolled

Carcinoma, Hepatocellular

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Phase 2 Enrolling by invitation

Nasopharyngeal Carcinoma

NCT05387512 2026-01-06

A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer

Completed

59 enrolled

Thoracic

Lung Neoplasms

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

48 enrolled

Phase 3 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

687 enrolled

Carcinoma, Hepatocellular

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

502 enrolled

Phase 2/3 Not yet recruiting

Pancreatic Neoplasms

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Not yet recruiting

1,300 enrolled

Cervical Cancer Metastatic

NCT06561308 2025-12-01

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

39 enrolled

Endometrioid Endometrial Cancer

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Other hematologic neoplasm

Carcinoma, Hepatocellular

NCT05772273 2025-11-21

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Phase NA Recruiting

43 enrolled

Leukemia, Myeloid, Acute

NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Phase 1/2 Active not recruiting

25 enrolled

Esophageal Neoplasms

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

120 enrolled

Cervical Cancer Metastatic

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

283 enrolled

Esophageal Neoplasms

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

41 enrolled

Esophageal Squamour Cell Cancer

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

885 enrolled

Stomach Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07100392 2025-08-17

LEAF-02

141 enrolled

Carcinoma, Hepatocellular

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT07057089 2025-08-14

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

90 enrolled

Locally Advanced Rectal Cancer

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

194 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Colonic Neoplasms

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Phase 2/3 Active not recruiting

28 enrolled

Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

294 enrolled

Carcinoma, Hepatocellular

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Phase 2 Enrolling by invitation

Advanced Gastric Cancer

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

50 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06288360 2025-03-20

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

40 enrolled

Uterine Cervical Neoplasms

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

60 enrolled

Dermatologic

Melanoma

NCT04299581 2025-02-27

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT06849492 2025-02-27

SHIFT-001

120 enrolled

Breast

Advanced Triple Negative Breast Cancer

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

369 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04649476 2025-01-10

NEOPBOSCC

68 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Pancreatic Neoplasms

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

35 enrolled